Mitigation

Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for LUMRYZ™ at SLEEP 2023

Retrieved on: 
Wednesday, May 31, 2023
Sodium oxybate, Orphan, Abstract, AASM, Central nervous system, American Academy of Sleep Medicine, Cataplexy, Doctor of Pharmacy, Sleep, Senior, Enuresis, Mitigation, EDS, Narcolepsy, Sleep Research Society, Food and Drug Administration, Weight loss, Severe cutaneous adverse reactions, American Academy, CIII, Approximation error, Vomiting, Incidence, Dizziness, Patient, Nausea, Poster, FDA, Health, Headache, Food, Pharmaceutical industry

DUBLIN, May 31, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced new data supporting the clinical profile for LUMRYZ™ (sodium oxybate) for extended-release oral suspension (CIII) and patient preference for a once-nightly oxybate in 12 abstracts, including six oral presentations, at SLEEP 2023, the 37th annual joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society, being held from June 3-7, 2023 in Indianapolis.

Key Points: 
  • DUBLIN, May 31, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced new data supporting the clinical profile for LUMRYZ™ (sodium oxybate) for extended-release oral suspension (CIII) and patient preference for a once-nightly oxybate in 12 abstracts, including six oral presentations, at SLEEP 2023, the 37th annual joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society, being held from June 3-7, 2023 in Indianapolis.
  • LUMRYZ was granted U.S. Food and Drug Administration (FDA) approval in May 2023, and is the first and only FDA approved once-at-bedtime oxybate for people living with narcolepsy.
  • “We are thrilled to attend SLEEP 2023 and present a broad range of data further supporting the clinical value proposition of LUMRYZ as a once-nightly option to manage EDS and cataplexy in narcolepsy, including data from our RESTORE and REST-ON trials,” said Jennifer Gudeman, PharmD, Senior Vice President, Medical and Clinical Affairs of Avadel.
  • LUMRYZ is available only through a restricted program under a Risk Evaluation and Mitigation Strategy called the LUMRYZ REMS.

Travelers Institute® to Host Cybersecurity Symposium in Charlotte, North Carolina

Retrieved on: 
Tuesday, May 23, 2023
Technology, Professional Services, Insurance, Security, The Travelers Companies, Education, Public policy, Culture, Cybersecurity and Infrastructure Security Agency, Traveler, Mitigation, Organization, Gambling, Small business, TRV, Conference, NYSE, Computer security, Risk management

The Travelers Institute , the public policy division of The Travelers Companies, Inc. (NYSE: TRV ), will host its in-person Cyber: Prepare, Prevent, Mitigate, Restore® symposium today, May 23, in Charlotte.

Key Points: 
  • The Travelers Institute , the public policy division of The Travelers Companies, Inc. (NYSE: TRV ), will host its in-person Cyber: Prepare, Prevent, Mitigate, Restore® symposium today, May 23, in Charlotte.
  • “As cyberattacks become more frequent and sophisticated, it’s essential that companies make a concerted effort to manage these threats,” said Joan Woodward, President of the Travelers Institute and Executive Vice President of Public Policy at Travelers.
  • “A recent Travelers survey found that only 29% of Charlotte businesses are cyber conscious.
  • Other speakers include Tim Francis, Vice President, Enterprise Cyber Lead at Travelers, and Jennifer Coughlin, Partner at Mullen Coughlin.

FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder

Retrieved on: 
Tuesday, May 23, 2023
Injection, REMS, Substance Abuse, Buprenorphine, Drug overdose, Education, Mitigation, Molina Healthcare, Senior counsel, Opioid use disorder, Skin, Substance Abuse and Mental Health Services Administration, Constipation, OUD, Urinary tract infection, Insomnia, Patient, Risk, Nausea, Drug, Diagnosis, FDA, Headache, Death, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Factitious disorder, Counterfeit, Food, Safety, SAMHSA, Pharmaceutical industry, Vaccine

"Buprenorphine is an important treatment option for opioid use disorder.

Key Points: 
  • "Buprenorphine is an important treatment option for opioid use disorder.
  • Today's approval expands dosing options and provides people with opioid use disorder a greater opportunity to sustain long-term recovery," said FDA Commissioner Robert M. Califf, M.D.
  • After an initial test dose of transmucosal buprenorphine, patients were randomized to treatment with Brixadi plus a sublingual placebo, or active sublingual buprenorphine plus placebo injections.
  • A response to treatment was measured by urine drug screening and self-reporting of illicit opioid use during the treatment period.

Braeburn's BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection (CIII) Receives FDA Approval for Moderate to Severe Opioid Use Disorder

Retrieved on: 
Tuesday, May 23, 2023
REMS, Mitigation, Pharmacy, Buprenorphine, Senior counsel, Health care, Opioid use disorder, OUD, SL, CIII, Heroin, Patient, Risk, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Vaccine, Pharmaceutical industry

PLYMOUTH MEETING, Pa., May 23, 2023 /PRNewswire/ -- Braeburn announces that the U.S. Food and Drug Administration (FDA) has approved BRIXADI (buprenorphine) extended-release injection for subcutaneous use (CIII), a new weekly and monthly medication for moderate to severe opioid use disorder (OUD) in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with a transmucosal buprenorphine-containing product. BRIXADI should be used as part of a complete treatment plan that includes counseling and psychosocial support. BRIXADI is to be administered only by healthcare providers in a healthcare setting and will be available in the U.S. in September 2023.

Key Points: 
  • Patients currently on a transmucosal buprenorphine-containing product can be switched to an equivalent dose of BRIXADI Weekly or Monthly.
  • BRIXADI is the first and only weekly and monthly subcutaneous injection for moderate to severe OUD and is the only buprenorphine injectable that utilizes FluidCrystal®* Injection Depot Technology.
  • "Today's FDA approval of BRIXADI is a significant step forward in the fight against OUD," said Mike Derkacz, President and CEO of Braeburn.
  • Additional medication options for opioid use disorder will support healthcare providers in addressing the needs of their patients with opioid use disorder."

New digital accessibility metrics launched by Lumar, a leading website intelligence and SEO platform

Retrieved on: 
Wednesday, May 17, 2023
URL, Marketing, Disability, Intelligence, World Wide Web Consortium, Mitigation, SEO, Organization, AAA, QA, WCAG, Service-level agreement, UX, WHO, Health, AA, World Health Organization, Online shopping, Publishing, Retail

NEW YORK, and LONDON, May 17, 2023 /PRNewswire/ -- Lumar, a leader in the website intelligence and technical SEO space, today announced the launch of new digital accessibility metrics and accessibility health scores within its website intelligence platform.

Key Points: 
  • NEW YORK, and LONDON, May 17, 2023 /PRNewswire/ -- Lumar, a leader in the website intelligence and technical SEO space, today announced the launch of new digital accessibility metrics and accessibility health scores within its website intelligence platform .
  • Powered by Lumar's ultra-fast proprietary website crawler and the leading digital accessibility library, axe®, the new website accessibility reports further expand Lumar's website intelligence offering beyond its origins as a major player in the technical SEO space.
  • Users can now examine technical SEO and website accessibility issues within a single platform.
  • With Lumar, digital teams can:
    Access a single source of truth for website intelligence: Technical SEO, accessibility, and other crucial website health issues can be viewed on a single platform.

New digital accessibility metrics launched by Lumar, a leading website intelligence and SEO platform

Retrieved on: 
Wednesday, May 17, 2023
URL, Marketing, Disability, Intelligence, World Wide Web Consortium, Mitigation, SEO, Organization, AAA, QA, WCAG, Service-level agreement, UX, WHO, Health, AA, World Health Organization, Online shopping, Publishing, Retail

NEW YORK, and LONDON, May 17, 2023 /PRNewswire/ -- Lumar, a leader in the website intelligence and technical SEO space, today announced the launch of new digital accessibility metrics and accessibility health scores within its website intelligence platform.

Key Points: 
  • NEW YORK, and LONDON, May 17, 2023 /PRNewswire/ -- Lumar, a leader in the website intelligence and technical SEO space, today announced the launch of new digital accessibility metrics and accessibility health scores within its website intelligence platform .
  • Powered by Lumar's ultra-fast proprietary website crawler and the leading digital accessibility library, axe®, the new website accessibility reports further expand Lumar's website intelligence offering beyond its origins as a major player in the technical SEO space.
  • Users can now examine technical SEO and website accessibility issues within a single platform.
  • With Lumar, digital teams can:
    Access a single source of truth for website intelligence: Technical SEO, accessibility, and other crucial website health issues can be viewed on a single platform.

Olatec Therapeutics Announces the Completion of First Dose Cohort in an Innovative Trial Investigating Olatec’s NLRP3 Inhibitor Dapansutrile and Merck’s Keytruda® in Patients with Advanced Refractory Melanoma at Duke Cancer Institute

Retrieved on: 
Tuesday, May 16, 2023
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Science, Oncology, DREAM, Human, PI, Frontiers, CSO, NLRP3, Immunotherapy, PFS, Mitigation, JCI, Publication, Patient, Melanoma, Cancer, Mouse, Merck, Neoplasm, Principal, PD-1, Pembrolizumab, Therapy, Rationale, ORR, Safety, Disease, Pharmaceutical industry, Vaccine, PNAS, Immunology

This trial is evaluating the combination treatment of Olatec’s dapansutrile, an NLRP3 inhibitor, and pembrolizumab (Keytruda®) in patients with PD-1 refractory advanced melanoma.

Key Points: 
  • This trial is evaluating the combination treatment of Olatec’s dapansutrile, an NLRP3 inhibitor, and pembrolizumab (Keytruda®) in patients with PD-1 refractory advanced melanoma.
  • The study is being led by Principal Investigator (PI), April Salama MD, Head of the Melanoma Program at The Duke Cancer Research Institute and supported by Olatec and Merck & Co., Inc. (Merck).
  • The aim of the DREAM Trial is to address the unmet need in patients with PD-1 refractory advanced melanoma.
  • Immunotherapy with immune checkpoint inhibitors (e.g., anti-PD-1 therapies) has transformed the treatment of melanoma, significantly improving the outcome of patients with this disease.

Tokyo International Fire and Safety Exhibition 2023

Retrieved on: 
Monday, May 15, 2023
Learning, Emergency service, Exhibition, URL, Tokyo Big Sight, Electricity, Service, NPO “Digital Television Systems”, Seminar, Fire, EVS, Organization, Disaster, Earthquake, Tokyo Fire Department, Executive Committee, Communication, Information system, Emergency, Tsunami, Mitigation, Tunnel, Nursing, Nightclub, Entertainment

TOKYO, May 15, 2023 - (JCN Newswire) - Tokyo Fire Department, Tokyo Big Sight Inc. and Tokyo International Fire and Safety Exhibition 2023 Executive Committee will hold the "Tokyo International Fire and Safety Exhibition 2023" at Tokyo Big Sight (East Halls 5, 6 and 7, Outdoor Exhibition Area, Offshore of Ariake-Nishi Port Park) from Thursday, June 15 to Sunday, June 18, 2023.

Key Points: 
  • TOKYO, May 15, 2023 - (JCN Newswire) - Tokyo Fire Department, Tokyo Big Sight Inc. and Tokyo International Fire and Safety Exhibition 2023 Executive Committee will hold the "Tokyo International Fire and Safety Exhibition 2023" at Tokyo Big Sight (East Halls 5, 6 and 7, Outdoor Exhibition Area, Offshore of Ariake-Nishi Port Park) from Thursday, June 15 to Sunday, June 18, 2023.
  • "Tokyo International Fire and Safety Exhibition 2023" is one of the largest fire and disaster prevention exhibitions in Japan, held once every five years.
  • + Outdoor Exhibition Area with impressive firefighting performances, and where kid's can have fun as they learn
    At the Outdoor Exhibition Area, in addition to corporate product exhibits, the Tokyo Fire Department will present powerful firefighting performances.
  • Various materials such as logos and photos from the previous exhibition can be downloaded from the URL below.

Terran Biosciences announces publication of four PCT patent applications covering breakthroughs in novel empathogens, including improved versions of methylone, ethylone, MDEA, MDAI, and MBDB

Retrieved on: 
Thursday, May 11, 2023
MDMC, REMS, MDAI, Depression, Therapy, MDEA, Mitigation, Methylone, Anxiety, Therapeutic index, Pathology, Pharmacokinetics, PCT, MDE, DSM-IV codes, Literature, OF, Patent, Patient, Post-traumatic stress disorder, USE, MBDB, Empathy, Salt, SALTS, MDMA, Safety, Pharmaceutical industry, Vaccine, Terran, PTSD

The discoveries include novel deuterated forms, enantiomerically pure forms, as well as novel salts, polymorphs, and co-crystals of racemic methylone, R-methylone and S-methylone.

Key Points: 
  • The discoveries include novel deuterated forms, enantiomerically pure forms, as well as novel salts, polymorphs, and co-crystals of racemic methylone, R-methylone and S-methylone.
  • Terran believes that therapeutic options for patients should be equally diverse, with unique psychedelics and empathogens tailored to specific patient needs.
  • Terran completed what is believed to be the first comprehensive salt and polymorph screen performed to date on this compound.
  • Terran completed additional improvements including the synthesis of deuterated forms of racemic methylone, R-methylone, and S-methylone with improved pharmacokinetics.

Seeing conservation solutions for unseen species

Retrieved on: 
Wednesday, May 10, 2023
Knowledge, Great Plains toad, Learning, ATK, Food, Cree, Breeding, Tree, Nakoda, Committee on the Status of Endangered Wildlife in Canada, Endangered species, Wind, Timber rattlesnake, Committee, California species of special concern, Eastern red bat, Tiger salamander, Frost, Pesticide, Hawaiian hoary bat, Climate change, Animal, Nature, Fern, Water, Gekkoninae, Mortality, COSEWIC, Mitigation, News, Hunting

COSEWIC, the Committee on the Status of Endangered Wildlife in Canada, met last week to consider the status of 16 wildlife species.

Key Points: 
  • COSEWIC, the Committee on the Status of Endangered Wildlife in Canada, met last week to consider the status of 16 wildlife species.
  • These included several that go unseen – those that are active in the night or that live underground or in hard-to-reach places.
  • Assessing secretive species underscores the importance of looking a little closer and learning all that we can to help them survive.
  • Several of the assessed species are not just hard to see but have actually gone unseen for decades.